We would like to share a brief update on the status of ELAHERE in Canada. As some of you may have seen, on September 4, 2025, Ovarian Cancer Canada posted an update on our social networks that Health Canada approved ELAHERE for certain types of platinum-resistant ovarian cancer. On September 22, 2025,
Canada's Drug Agency (CDA) released their draft recommendation for ELAHERE which was to reimburse with conditions. This was welcome news to our community, and the review process is ongoing for both CDA and INESSS, the equivalent of the CDA in Quebec.
Because ELAHERE is still not currently available in Canada, health care professionals in Canada can request a drug that is not available for sale through
Health Canada's Special Access Program (SAP). Health care professionals must complete and sign
the SAP request form.
Patients who would like more information should speak directly with their health care team.
Ovarian Cancer Canada continues to advocate for ELAHERE to become available to Canadians and we will continue to share updates with our community as they become available.
-------------------------------------------